Kelly Jared 4

What Happened
Jared Kelly, Chief Executive Officer of Oncolytics Biotech Inc. (ONCY), made two open-market purchases (transaction code P) totaling 35,100 shares: 5,600 shares on 2026-02-11 and 29,500 shares on 2026-02-12. The reported weighted-average price is $0.84 per share; total cash outlay across both transactions was about $29,521. These were purchases (insider buying), which many investors view as a potentially positive signal, though it does not prove future performance.

Key Details

• Transaction dates and amounts:
  • 2026-02-11: 5,600 shares at a weighted average price reported as $0.84 — value $4,682.
  • 2026-02-12: 29,500 shares at a weighted average price reported as $0.84 — value $24,839.
• Combined: 35,100 shares for ~$29,521; reported weighted average price $0.84.
• Footnote: The $0.84 price is a weighted average; actual trade prices ranged from $0.820 to $0.856. The filer offers to provide a breakdown on request (Footnote F1).
• Shares owned after the transactions: Not disclosed in the provided filing excerpt.
• Timeliness: Filing dated 2026-02-13 appears timely relative to the trade dates (no late‑filing indication in the provided info).

Context
These were open-market purchases (code P), not option exercises, gifts, or awards. Insider buys are factual data points investors track as one signal of insider conviction, but they should be considered along with company fundamentals and other information before making investment decisions.